Patents Assigned to Curasight A/S
  • RADIONUCLIDE LABELLED PEPTIDE CONJUGATE FOR SITE-SPECIFIC UPAR-TARGETING
    Publication number: 20260224762
    Abstract: The present invention provides a radionuclide labelled peptide for site-specific targeting of the Urokinase Plasminogen Activator Receptor (uPAR) and treatment of cancer diseases associated with high uPAR expression.
    Type: Application
    Filed: January 18, 2024
    Publication date: August 6, 2026
    Applicant: CURASIGHT A/S
    Inventor: Andreas KJÆR
  • Positron emitting radionuclide labeled peptides for human uPAR PET imaging
    Patent number: 12409240
    Abstract: There is provided a positron-emitting radionuclide labelled peptide for non-invasive PET imaging of the Urokinase-type Plasminogen Activator Receptor (uPAR) in humans. More specifically the invention relates to human uPAR PET imaging of any solid cancer disease for diagnosis, staging, treatment monitoring and especially as an imaging biomarker for predicting prognosis, progression and recurrence.
    Type: Grant
    Filed: March 17, 2022
    Date of Patent: September 9, 2025
    Assignee: CURASIGHT A/S
    Inventors: Andreas Kjaer, Morten Persson, Jacob Madsen
  • POSITRON EMITTING RADIONUCLIDE LABELED PEPTIDES FOR HUMAN UPAR PET IMAGING
    Publication number: 20220202966
    Abstract: There is provided a positron-emitting radionuclide labelled peptide for non-invasive PET imaging of the Urokinase-type Plasminogen Activator Receptor (uPAR) in humans. More specifically the invention relates to human uPAR PET imaging of any solid cancer disease for diagnosis, staging, treatment monitoring and especially as an imaging biomarker for predicting prognosis, progression and recurrence.
    Type: Application
    Filed: March 17, 2022
    Publication date: June 30, 2022
    Applicant: CURASIGHT A/S
    Inventors: Andreas KJAER, Morten PERSSON, Jacob MADSEN
  • Positron emitting radionuclide labeled peptides for human uPAR PET imaging
    Patent number: 11311637
    Abstract: There is provided a positron-emitting radionuclide labelled peptide for non-invasive PET imaging of the Urokinase-type Plasminogen Activator Receptor (uPAR) in humans. More specifically the invention relates to human uPAR PET imaging of any solid cancer disease for diagnosis, staging, treatment monitoring and especially as an imaging biomarker for predicting prognosis, progression and recurrence.
    Type: Grant
    Filed: May 8, 2020
    Date of Patent: April 26, 2022
    Assignee: Curasight A/S
    Inventors: Andreas Kjaer, Morten Persson, Jacob Madsen